Yes, Start a Beta-Blocker Immediately
In a patient with stable coronary artery disease and heart failure with reduced ejection fraction, a guideline-directed beta-blocker should be started despite the resting heart rate of 52 bpm, as the mortality and morbidity benefits far outweigh concerns about relative bradycardia in this population. 1, 2, 3
Why Beta-Blockers Are Essential in HFrEF
The 2022 AHA/ACC/HFSA guidelines establish beta-blockers as one of the four foundational pillars of guideline-directed medical therapy (GDMT) for HFrEF, alongside SGLT2 inhibitors, ACE inhibitors/ARNIs, and mineralocorticoid receptor antagonists 1, 2. This Class I recommendation (Level of Evidence A) applies to all patients with current or prior symptoms of HFrEF unless contraindicated 4, 5.
The evidence base is robust: multiple landmark trials (CIBIS II, MERIT-HF, COPERNICUS, CAPRICORN) demonstrated that beta-blockers:
- Increase survival
- Reduce hospital admissions
- Improve NYHA functional class and quality of life 6
Addressing the Heart Rate of 52 bpm
A resting heart rate of 52 bpm is listed as a "caution" requiring specialist advice, not an absolute contraindication 6. The 2025 European Heart Failure Association consensus specifically addresses this scenario, recommending beta-blocker initiation when heart rate is >50 bpm 7.
Key Nuances:
- The older 2001 guidelines listed HR <60/min as a caution requiring specialist input 6
- Contemporary practice recognizes that asymptomatic bradycardia should not prevent GDMT initiation 7
- The 2025 consensus explicitly states: "Asymptomatic or mildly symptomatic low BP should not be a reason for GDMT reduction or cessation" 7
- Beta-blockers can be up-titrated if HR >50 bpm 7
Which Beta-Blocker and How to Start
Only three beta-blockers have proven mortality reduction in heart failure - this is NOT a class effect 6, 4, 6:
| Beta-blocker | Starting Dose | Target Dose |
|---|---|---|
| Bisoprolol | 1.25 mg once daily | 10 mg once daily |
| Carvedilol | 3.125 mg twice daily | 25-50 mg twice daily |
| Metoprolol succinate CR/XL | 12.5-25 mg once daily | 200 mg once daily |
Practical Initiation Strategy
- Start with the lowest dose from the table above
- Monitor closely: heart rate, blood pressure, symptoms, signs of congestion, body weight 6
- Double the dose at minimum 2-week intervals 6
- Aim for target dose or highest tolerated dose 6
- Check blood chemistry at 1-2 weeks after initiation and after final dose titration 6
Critical Point:
"Some beta-blocker is better than no beta-blocker" - even if target doses cannot be achieved, lower doses provide meaningful benefit 6.
Patient Counseling
Inform the patient that:
- Symptomatic improvement may take 3-6 months or longer 6
- Temporary worsening may occur in 20-30% during initiation (fatigue, breathlessness) 6
- Treatment prevents disease progression and increases survival, not just symptom relief 6
- They should not stop the medication without consulting you if symptoms worsen 6
Common Pitfalls to Avoid
Do not withhold beta-blockers due to:
- Asymptomatic bradycardia with HR >50 bpm 7
- Mild hypotension without symptoms 7
- Fear of worsening heart failure (beta-blockers improve outcomes even in severe HF) 6
Do seek specialist advice for:
- NYHA Class IV severe heart failure 6
- Recent decompensation within 4 weeks 6
- Heart block 6
- Persistent signs of congestion (elevated JVP, ascites, marked edema) 6
The Coronary Artery Disease Component
While beta-blockers were traditionally considered cardioprotective in stable CAD, contemporary evidence shows their prognostic benefit in CAD without LV dysfunction is limited 8, 9, 10, 11. However, this patient has both stable CAD and HFrEF - the HFrEF indication alone mandates beta-blocker therapy with strong Class I evidence 4, 5, 1.
The presence of HFrEF makes beta-blocker therapy non-negotiable, regardless of the concurrent stable CAD.